The Enterprise Value as of December 2025 (TTM) for Entrada Therapeutics, Inc. (TRDA) is 347.42M

According to Entrada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 347.42M. This represents a change of -6.37% compared to the average of 371.07M of the last 4 quarters.

Entrada Therapeutics, Inc. (TRDA) Historical Enterprise Value (quarterly & annually)

How has TRDA Enterprise Value performed in the past?

The mean historical Enterprise Value of Entrada Therapeutics, Inc. over the last ten years is 411.23M. The current 347.42M Enterprise Value has changed 8.35% with respect to the historical average. Over the past ten years (40 quarters), TRDA's Enterprise Value was at its highest in in the December 2024 quarter at 664.17M. The Enterprise Value was at its lowest in in the June 2020 quarter at 0.

Entrada Therapeutics, Inc. (TRDA) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Entrada Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Entrada Therapeutics, Inc. (TRDA) Average Enterprise Value

How has TRDA Enterprise Value performed in the past?

The current Enterprise Value of Entrada Therapeutics, Inc. (TRDA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Entrada Therapeutics, Inc. (TRDA) Enterprise Value vs. Peers

How is TRDA’s Enterprise Value compared to its peers?

Entrada Therapeutics, Inc.’s Enterprise Value is greater than Humacyte, Inc. (196.00M), greater than Achieve Life Sciences, Inc. (232.44M), greater than Voyager Therapeutics, Inc. (235.09M), greater than Vanda Pharmaceuticals Inc. (243.49M), greater than Atea Pharmaceuticals, Inc. (154.94M), greater than Arcturus Therapeutics Holdings Inc. (26.78M), less than Capricor Therapeutics, Inc. (1.14B), greater than Sagimet Biosciences Inc. (164.48M), greater than Immuneering Corporation (220.51M), less than Allogene Therapeutics, Inc. (362.93M),

Build a custom stock screener for Entrada Therapeutics, Inc. (TRDA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Entrada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Entrada Therapeutics, Inc. (TRDA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Entrada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.